21 May 2013 - 21 May 2013 - Canadian SQI Diagnostics Inc (CVE:SQD) booked today a net loss of CAD 1.35 million (USD 1.3m/EUR 1m) for its second quarter to 31 March, unchanged from the same period last year.

Loss per share stood at CAD 0.03 against CAD 0.04 in the prior year period.

The company's chief financial officer Andrew Morris said that SQI has advanced its "large pharma" sales strategy and that the firm believes that it will generate sales for its Diagnostic Tools and Services unit during the current year.

Currently, the company is targeting clients mainly involved in drug development and clinical research which would utilise SQI's technology to perform anti-drug-antibody (ADA) or biomarker testing.

(CAD 1.0 = USD 0.973/EUR 0.757)